# A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

> **NCT04424641** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 48 (actual)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumor(s)
- Prostate Cancer
- Esophageal Cancer
- Triple Negative Breast Cancer (TNBC)
- Squamous Cell Carcinoma of Head and Neck (SCCHN)
- Non-small Cell Lung Cancer (NSCLC)
- Bladder Cancer
- Uterine Cancer

## Interventions

- **BIOLOGICAL:** GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.

## Key facts

- **NCT ID:** NCT04424641
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-15
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Study was terminated due to MTD was reached
- **Last updated:** 2023-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04424641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04424641, "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04424641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*